Trials / Terminated
TerminatedNCT01598038
Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell Carcinoma
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Centre Francois Baclesse · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators hypothesize everolimus toxicities are linked to pharmacokinetic variabilities of everolimus. Thus, early detection of clinical or biological risk factors will lead to personalized dosage treatment and permit a better tolerance without altering efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Blood sample | Everolimus is determined in whole blood by validated high performance liquid chromatography with tandem mass spectrometry after protein precipitation |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2015-03-01
- Completion
- 2015-12-01
- First posted
- 2012-05-15
- Last updated
- 2017-07-28
Locations
2 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01598038. Inclusion in this directory is not an endorsement.